Yokoi, Takashi

Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer

Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

Cited by 4,593

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Garassino, M. C., Cho, B.-C., Kim, J.-H., Mazières, J., Vansteenkiste, J., Lena, H., Corral Jaime, J., Gray, J. E., Powderly, J., Chouaid, C., et al. (2018) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 568

Adenosine Deaminase in Pleural Effusion and Its Relationship with Clinical Parameters in Patients with Malignant Pleural Mesothelioma

Nakajima, Y., Kuribayashi, K., Ishigaki, H., Tada, A., Negi, Y., Minami, T., Takahashi, R., Doi, H., Kitajima, K., Yokoi, T., et al. (2020) · Cancer Investigation

Occupational and environmental lung diseasesPleural and Pulmonary Diseases

Cited by 13